MLN120B dihydrochloride是一种口服有效的ATP竞争性IKKβ抑制剂，可在体外和体内抑制多发性骨髓瘤细胞生长，并用于类风湿关节炎研究。

[1] Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 1;12(19):5887-94. doi: 10.1158/1078-0432.CCR-05-2501. PMID: 17020997.